{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:01:22Z","timestamp":1694631682412},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s11864-006-0002-0","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T18:18:46Z","timestamp":1183573126000},"page":"346-354","source":"Crossref","is-referenced-by-count":1,"title":["Should finasteride be used to prevent prostate cancer?"],"prefix":"10.1007","volume":"7","author":[{"given":"Neil","family":"Fleshner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2_CR1","first-page":"211","volume":"27","author":"HB Burke","year":"2005","unstructured":"Burke HB, Bostwick DG, Meiers I, Montironi R: Prostate cancer outcome: epidemiology and biostatistics. Anal Quant Cytol Histol 2005, 27:211\u2013217.","journal-title":"Anal Quant Cytol Histol"},{"key":"2_CR2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jnci\/50.5.1137","volume":"50","author":"K Akazaki","year":"1973","unstructured":"Akazaki K, Stemmermann G: Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973, 50:1137\u20131144.","journal-title":"J Natl Cancer Inst"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.urology.2005.09.006","volume":"67","author":"SA Arredondo","year":"2006","unstructured":"Arredondo SA, Elkin EP, Marr PL, et al.: CaPSURE Investigators. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology 2006, 67:559\u2013565.","journal-title":"Urology"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0022-5347(17)35487-3","volume":"150","author":"W Sakr","year":"1993","unstructured":"Sakr W, Haas G, Cassin B: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379\u2013385.","journal-title":"J Urol"},{"key":"2_CR5","first-page":"249","volume":"370","author":"CP Wu","year":"1991","unstructured":"Wu CP, Gu FL: The prostate in eunuchs. Prog Clin Biol Res 1991, 370:249\u2013255.","journal-title":"Prog Clin Biol Res"},{"key":"2_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2174\/138161206776056056","volume":"12","author":"SS Wilson","year":"2006","unstructured":"Wilson SS, Crawford ED: Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 2006, 12:799\u2013805.","journal-title":"Curr Pharm Des"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0022-5347(05)00041-8","volume":"175","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, McConnell JD, Roehrborn CG, et al.: Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006, 175:217\u2013220.","journal-title":"J Urol"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215\u2013224. This key article reports the results of the PCPT using finasteride.","journal-title":"N Engl J Med"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0022-5347(01)63946-6","volume":"159","author":"J Pannek","year":"1998","unstructured":"Pannek J, Marks LS, Pearson JD, et al.: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998, 159:449\u2013453.","journal-title":"J Urol"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","volume":"293","author":"PC Albertsen","year":"2005","unstructured":"Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095\u20132101.","journal-title":"JAMA"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","volume":"23","author":"DF Gleason","year":"1992","unstructured":"Gleason DF: Histological grading of prostate cancer: a perspective. Hum Pathol 1992, 23:273\u2013279.","journal-title":"Hum Pathol"},{"key":"2_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01.pap.0000202017.78917.18","volume":"13","author":"JI Epstein","year":"2006","unstructured":"Epstein JI, Allsbrook WC, Amin MB, Egevad LL: Update on Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006, 13:57\u201359.","journal-title":"Adv Anat Pathol"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00000478-199410000-00002","volume":"18","author":"OA Armas","year":"1994","unstructured":"Armas OA, Aprikian AG, Melamed J, et al.: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994, 18:979\u2013991.","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 2","key":"2_CR14","first-page":"22","volume":"4","author":"F Civantos","year":"1996","unstructured":"Civantos F, Soloway MS, Pinto JE: Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996, 4(Suppl 2):22\u201331.","journal-title":"Semin Urol Oncol"},{"key":"2_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S0090-4295(98)00579-2","volume":"53","author":"XJ Yang","year":"1999","unstructured":"Yang XJ, Lecksell K, Short K, et al.: Does long-term finasteride affect the histological features of benign prostate tissue and prostate cancer on needle biopsy? PLESS study group. Urology 1999, 53:696\u2013700.","journal-title":"Urology"},{"key":"2_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.urology.2005.07.036","volume":"66","author":"MA Rubin","year":"2005","unstructured":"Rubin MA, Allory Y, Molinie V, et al.: Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005, 66:930\u2013934.","journal-title":"Urology"},{"key":"2_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0022-5347(05)00236-3","volume":"175","author":"GS Kulkarni","year":"2006","unstructured":"Kulkarni GS, Al-Azab R, Lockwood G, et al.: Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006, 175:505\u2013509. This key publication first describes the volume\/grade artifact.","journal-title":"J Urol"},{"key":"2_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0090-4295(98)00567-6","volume":"53","author":"LS Marks","year":"1999","unstructured":"Marks LS, Partin AW, Dorey FJ, et al.: Long-term effects of finasteride on prostate tissue composition. Urology 1999, 53:574\u2013580.","journal-title":"Urology"},{"key":"2_CR19","first-page":"153","volume":"175","author":"IM Thompson","year":"2006","unstructured":"Thompson IM, Chen C, Goodman P, et al.: Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the prostate cancer prevention trial. J Urol 2006, 175:153.","journal-title":"J Urol"},{"key":"2_CR20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.urolonc.2004.04.009","volume":"22","author":"JM Unger","year":"2004","unstructured":"Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr: The person-years saved model and other methodologies for assessing the population impact of cancerprevention strategies. Urol Oncol 2004, 22:362\u2013368. This was the first decision analysis based on PCPT data.","journal-title":"Urol Oncol"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1200\/JCO.2005.03.137","volume":"23","author":"Y Lotan","year":"2005","unstructured":"Lotan Y, Cadeddu JA, Lee JJ, et al.: Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 2005, 23:1911\u20131920.","journal-title":"J Clin Oncol"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.amjmed.2005.03.001","volume":"118","author":"SB Zeliadt","year":"2005","unstructured":"Zeliadt SB, Etzioni RD, Penson DF, et al.: Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005, 118:850\u2013857.","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"2_CR23","first-page":"2","volume":"12","author":"N Fleshner","year":"2005","unstructured":"Fleshner N, Al Azab R: Prostate cancer: chemoprevention update 2005. Can J Urol 2005, 12(Suppl 2):2\u20134.","journal-title":"Can J Urol"},{"key":"2_CR24","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/01.ju.0000107838.33623.19","volume":"171","author":"N Fleshner","year":"2004","unstructured":"Fleshner N, Bagnell PS, Klotz L, Venkateswaran V: Dietary fat and prostate cancer. J Urol 2004, 171:S19-S24.","journal-title":"J Urol"},{"key":"2_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/01.ju.0000169487.49018.73","volume":"174","author":"D Ornish","year":"2005","unstructured":"Ornish D, Weidner G, Fair WR, et al.: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005, 174:1065\u20131069; discussion 1069-1070.","journal-title":"J Urol"},{"key":"2_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0094-0143(02)00023-X","volume":"29","author":"NE Fleshner","year":"2002","unstructured":"Fleshner NE: Vitamin E and prostate cancer. Urol Clin North Am 2002, 29:107\u2013113, ix.","journal-title":"Urol Clin North Am"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/jnci\/90.6.440","volume":"90","author":"OP Heinonen","year":"1998","unstructured":"Heinonen OP, Albanes D, Virtamo J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440\u2013446.","journal-title":"J Natl Cancer Inst"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","volume":"142","author":"ER Miller","year":"2005","unstructured":"Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Metaanalysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37\u201346.","journal-title":"Ann Intern Med"},{"key":"2_CR29","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","volume":"293","author":"E Lonn","year":"2005","unstructured":"Lonn E, Bosch J, Yusuf S, et al.: HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338\u20131347.","journal-title":"JAMA"},{"key":"2_CR30","first-page":"91","volume":"17","author":"MA Nelson","year":"1999","unstructured":"Nelson MA, Porterfield BW, Jacobs ET, Clark LC: Selenium and prostate cancer prevention. Semin Urol Oncol 1999, 17:91\u201396.","journal-title":"Semin Urol Oncol"},{"key":"2_CR31","first-page":"2540","volume":"62","author":"V Venkateswaran","year":"2002","unstructured":"Venkateswaran V, Klotz LH, Fleshner NE: Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002, 62:2540\u20132545.","journal-title":"Cancer Res"},{"key":"2_CR32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S0090-4295(97)00339-7","volume":"50","author":"WR Fair","year":"1997","unstructured":"Fair WR, Fleshner NE, Heston W: Cancer of the prostate: a nutritional disease. Urology 1997, 50:840\u2013848.","journal-title":"Urology"},{"key":"2_CR33","doi-asserted-by":"crossref","first-page":"2030S","DOI":"10.1093\/jn\/135.8.2030S","volume":"135","author":"E Giovannucci","year":"2005","unstructured":"Giovannucci E: Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005, 135:2030S-2031S.","journal-title":"J Nutr"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/14796694.1.3.425","volume":"1","author":"M Ansari","year":"2005","unstructured":"Ansari M, Ansari S: Lycopene and prostate cancer. Future Oncol 2005, 1:425\u2013430.","journal-title":"Future Oncol"},{"key":"2_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00042307-200401000-00004","volume":"14","author":"F Desgrandchamps","year":"2004","unstructured":"Desgrandchamps F: Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 2004, 14:17\u201320.","journal-title":"Curr Opin Urol"},{"key":"2_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","volume":"150","author":"BS Carter","year":"1993","unstructured":"Carter BS, Bova GS, Beaty TH, et al.: Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993, 150:797\u2013802.","journal-title":"J Urol"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/0008-5472.CAN-06-0168","volume":"66","author":"SA Tomlins","year":"2006","unstructured":"Tomlins SA, Mehra R, Rhodes DR, et al.: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66:3396\u20133400.","journal-title":"Cancer Res"},{"key":"2_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ijc.20578","volume":"113","author":"E Spangler","year":"2005","unstructured":"Spangler E, Zeigler-Johnson CM, Malkowicz SB, et al.: Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer 2005, 113:471\u2013474.","journal-title":"Int J Cancer"},{"key":"2_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0302-2838(02)00256-7","volume":"42","author":"B Djavan","year":"2002","unstructured":"Djavan B, Remzi M, Schulman CC, et al.: Repeat prostate biopsy: who, how and when? A review. Eur Urol 2002, 42:93\u2013103.","journal-title":"Eur Urol"},{"key":"2_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0022-5347(05)00280-6","volume":"175","author":"T Patel","year":"2006","unstructured":"Patel T, Huang G, Lepor H, Taneja SS: Are cancers diagnosed in long-term follow up of HGPIN clinically significant. J Urol 2006, 175:480.","journal-title":"J Urol"},{"key":"2_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0022-5347(05)00337-X","volume":"175","author":"JI Epstein","year":"2006","unstructured":"Epstein JI, Herawi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006, 175:820\u2013834.","journal-title":"J Urol"},{"key":"2_CR42","first-page":"55","volume":"16","author":"RA Jones","year":"2005","unstructured":"Jones RA, Wenzel J: Prostate cancer among African-American males: understanding the current issues. J Natl Black Nurses Assoc 2005, 16:55\u201362.","journal-title":"J Natl Black Nurses Assoc"},{"key":"2_CR43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1442-2042.2005.01111.x","volume":"12","author":"Roy S Dutta","year":"2005","unstructured":"Dutta Roy S, Philip J, Javle P: Trends in prostate cancer incidence and survival in various socioeconomic classes: a population-based study. Int J Urol 2005, 12:644\u2013653.","journal-title":"Int J Urol"},{"key":"2_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/13543784.15.3.293","volume":"15","author":"SS Taneja","year":"2006","unstructured":"Taneja SS, Smith MR, Dalton JT, et al.: Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 2006, 15:293\u2013305.","journal-title":"Expert Opin Investig Drugs"},{"key":"2_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/jnci\/dji009","volume":"97","author":"SM Lippman","year":"2005","unstructured":"Lippman SM, Goodman PJ, Klein EA, et al.: Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst 2005, 97:94\u2013102.","journal-title":"J Natl Cancer Inst"},{"key":"2_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.urology.2004.04.084","volume":"64","author":"GL Andriole","year":"2004","unstructured":"Andriole GL, Roehrborn C, Schulman C, et al.: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004, 64:537\u2013541; discussion 542-543.","journal-title":"Urology"},{"key":"2_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/pros.20188","volume":"63","author":"LN Thomas","year":"2005","unstructured":"Thomas LN, Lazier CB, Gupta R, et al.: Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005, 63:231\u2013239.","journal-title":"Prostate"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-006-0002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0002-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:14:02Z","timestamp":1652624042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-006-0002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s11864-006-0002-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}